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WIn this issue of The Annals of Thoracic Surgery, Malvindi
and colleagues1 are to be congratulated for their brave,
insightful, and yet puzzling exercise to systematically
review reported outcomes after bioprosthetic mitral valve
replacement.
Why is it brave? Because of the complexity of the
topic—mitral valve replacement, unlike aortic valve
replacement, is not a golden standard but is reserved for
patients in whom repair is not possible, which is a het-
erogeneous group. In addition, during the long time span
of the study—over 35 years—mitral valve surgery practice
dramatically changed, as did patient profile and life ex-
pectancy in all parts of the world. Add the multiple bio-
prostheses that were investigated, and the major
methodological challenges that we still face when trying
to assess their durability, and that makes this systematic
review a brave exercise indeed.
Why is it insightful, yet puzzling? The study provides
an in-depth overview—both historical and more
contemporary—of both patient survival and freedom
from structural valve deterioration (SVD) for different
mitral valve bioprostheses. The main message from this
study is that the data suggest both superior survival and
freedom from SVD in patients receiving the Mosaic
valve. But why would patients with a Mosaic valve live
longer? Is this due to patient selection, optimal valve
hemodynamics, or a combination? And why would these
longer-living Mosaic patients experience less SVD? Pa-
tient mortality and SVD are competing risks, and in a
population with a low mortality rate usually SVD
occurrence will be higher compared with populations
with a higher mortality rate.2 Is it because the Mosaic
valve is extremely durable, even in “very durable” pa-
tients? Or is it because the mean follow-up duration of 3
of the 4 included Mosaic studies is less than 3 years?
Perhaps the methodological flaws that are inherent to
systematic reviews of mainly retrospective observational
and heterogeneous data play an important role. Or is it
in the employed definition of SVD? The authors report
that only 23 of the 40 included papers reported SVD
according to the Akins guidelines for mortality andmorbidity after cardiac valve intervention.3 A closer look
at the interpretation of these guidelines in the 23 indi-
vidual papers that report to follow the Akins guidelines
(in their Supplemental Table 2) reveals that some use
SVD diagnosis, some use SVD reoperation, and some
use SVD reoperation and SVD at autopsy. These
different interpretations of SVD can result in different
SVD outcomes estimates. SVD reoperation for example
can be viewed as a “hard” endpoint, but actually it is not
an endpoint and is instead a clinical decision that was
based on a diagnosis and the consideration of other
clinical factors (and hopefully patient preferences), and
not all patients with diagnosed SVD will undergo reop-
eration. SVD diagnosis on the other hand might not
necessarily be considered an endpoint because the
measurement of valve dysfunction can vary over time,
and it should ideally be modeled using longitudinal
modeling techniques.3
Malvindi and colleagues in their brave attempt to give
an overview of outcomes after bioprosthetic mitral valve
replacement have succeeded in painting a historical and
contemporary picture, and at the same time have left us
with many missing puzzle pieces to be found.
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